Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Bronchial brushings for investigating airway inflammation and remodelling

Asthma is the commonest medical cause for hospital admission for children in Australia, affects more than 300 million people worldwide, and is incurable...

Research

Does Exposure to Asbestos Cause Ovarian Cancer? A Systematic Literature Review and Meta-analysis

The asbestos and ovarian cancer relationship is not well understood because of small numbers of women exposed to asbestos, small numbers of cases...

Research

Opportunities and challenges of the pulmonary route for vaccination

The respiratory tract is an attractive target for the delivery of vaccine antigens.

Research

Soluble Glycoprotein VI Is Raised in the Plasma of Patients With Acute Ischemic Stroke

schemic stroke induced by thrombosis may be triggered by atherosclerotic plaque rupture and collagen-induced platelet activation. Collagen induces...

Research

Adult psychosocial outcomes of children with specific language impairment, pragmatic language impairment and autism

Evidence that some children also develop autistic symptomatology over time has raised suggestions that developmental language disorder...

Research

The common BDNF polymorphism may be a modifier of disease severity in Rett syndrome

Rett syndrome (RTT) is caused by mutations in the transcriptional repressor methyl CpG-binding protein 2 (MECP2).

Research

Siblings of children with disabilities: challenges and opportunities

Siblings of children with disabilities: challenges and opportunities

Research

Investigations into the role of ST2 in acute asthma in children

This study investigated the potential role of ST2 in children with acute asthma.

Research

Hypoglycemia alarm enhancement using data fusion

The acceptance of closed-loop blood glucose (BG) control using continuous glucose monitoring systems (CGMS) is likely to improve.

Research

Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy

Topical application of tumors with the TLR7 agonist imiquimod is an effective adjunct treatment for a range of primary dermatological cancers.